SCHOFIELD, Wis., April 14, 2011 (GLOBE NEWSWIRE) -- PuraMed BioScience, Inc. (OTCQB:PMBS) is providing an update to its shareholders regarding the next steps in introducing its non-prescription migraine product, LipiGesic™ M, to the national retail market.
"Now that we have confirmation that our clinical study has been accepted for publication in a top-ranked medical journal, we are initiating contact with top national retail outlets in the drug, mass and food categories to introduce LipiGesic™ M and to secure shelf placement of our product," said PuraMed BioScience CEO Russell Mitchell. "We are confident we can make our product available nationally, and the timing couldn't be better as LipiGesic™ M is expected to gain visibility through our study's publication in a top-ranked medical journal."
"We are pleased that we are continuing to achieve the milestones we have identified as a Company," Mitchell continued. "We look forward to additional developments in the near-term and will be pleased to share those with our stakeholders as soon as they become available."
About PuraMed BioScience, Inc.:
PuraMed BioScience, Inc. engages in the research, development and marketing of non-prescription medicinal and healthcare products. In addition to its leading product LipiGesic™ M, which provides acute relief from migraine headaches, the Company also has plans to launch LipiGesic™ PM that provides a remedy for insomnia and other sleep disorders as well as LipiGesic™ H for tension-type headaches. For more information on PuraMed, visit the Company website at www.PuraMedBioScience.com, join the Company's group page on Facebook by searching "PuraMed BioScience" and follow the Company on Twitter at www.twitter.com/puramed.
Forward Looking Statements:
This news release contains forward-looking statements regarding PuraMed BioScience and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed BioScience to be materially different than those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.